ISO 18562 Testing

Biocompatibility Evaluation of Breathing Gas Pathways in Healthcare Applications 

What is it and Why is it Important?

ISO 18562 is the standard for toxicity studies in respiratory devices and components required by the regulatory bodies of the United States and European Union. The testing searches for three sources of potentially hazardous materials that are being emitted by the device and/or its components. The emission of these hazardous particles could enter the respiratory system, causing dangerous conditions for the patient.

Scroll down for more infomation

The three areas of this standard are as follows and are all conducted at PSN:

ISO Certified Labs

Our state-of-the-art Testing Laboratory is ISO/IEC 17025:2017 accredited and fully equipped to support all your material and product testing needs.


Our lab operates as a stand-alone service, as well as being integrated into our full spectrum of engineering services.


PSN’s experience and expertise crosses over a wide range of industries, products, and manufacturing processes, allowing our team to be a best-in-class choice to help determine and correct the risks associated with device manufacturing.

ISO 18562

In 2017, ISO 18562 was released and added to ISO 10993-1 as the standard for toxicity studies in respiratory devices and components, required by United States and European Union regulatory bodies. The standard analyzes three areas of potentially hazardous materials:


ISO 18562-2: Particles

ISO 18562-3: VOCs

ISO 18562-4: Leachables


The PSN Test Lab is equipped with industry leading equipment for qualification of devices and the generation of data for FDA submissions. At PSN, we are so much more than just a test lab. Our team of scientists and engineers are trained to isolate confounding variables and provide clear analysis to guide the commercialization of new medical devices.

Plastics Services Network (PSN)


5368 Kuhl Road
Erie, PA 16510
Email: info@PSNLabs.com
Phone: 814.464.0790
Fax: 814.464.0794

Go to article: Home | The triumph of telemedicineGo to article: In This IssueGo to article: BioInteractions Company Insight Go to article: BioInteractions Go to article: ContentsGo to article: ElectroCraft Company InsightGo to article: ElectroCraftGo to article: NewsGo to article: Coronavirus Executive BriefingGo to article: Helbling Go to article: Phosphorus and BioIQ announce partnership for at-home Covid-19 testing kitsGo to article: Roche’s Covid-19 tests could be enough to offset losses during lockdownGo to article: CRISPR biotechnology set to disrupt Covid-19 testing marketGo to article: Resumption of elective surgeries in the US to be short-livedGo to article: Abbott’s ID NOW Covid-19 test under questionGo to article: Sandvik Company InsightGo to article: Sandvik Go to article: The medical industry briefingGo to article: Mus musculus: how nanofluidic drug delivery could counter muscle loss in spaceGo to article: Coding in medtech: setting standards for the digital ageGo to article: SartoriusGo to article: Will digital mental health solutions thrive after Covid-19?Go to article: South Korea: the rise of a new medtech giant? Go to article: ICF MercantileGo to article: Is there a bright future for telemedicine in a post-Covid world?Go to article: PSN LabsGo to article: Q&A: discussing cancer blood testing tech with VolitionGo to article: dokspotGo to article: What does the MDR delay mean for the European medtech sector?Go to article: Covid-19 immunity passports: how to protect health dataGo to article: The key list powered by GlobalDataGo to article: Deals in brief powered by GlobalDataGo to article: TS Quality & EngineeringGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2 ) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next Issue